Kura Oncology to Participate in Three Upcoming Investor Conferences
30 oct. 2023 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Third Quarter 2023 Financial Results
26 oct. 2023 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806
19 oct. 2023 07h30 HE
|
Kura Oncology, Inc.
– Phase 1 dose-escalation study to evaluate KO-2806 as a monotherapy and in combination with targeted therapies in KRASG12C-mutant NSCLC and ccRCC – SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) --...
Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC
17 oct. 2023 16h05 HE
|
Kura Oncology, Inc.
– Meaningful antitumor activity observed in recurrent/metastatic HRAS mutant HNSCC, including CR – – Data validate activity of farnesyltransferase inhibitors and support rapid advancement of KO-2806...
Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
04 oct. 2023 07h30 HE
|
Kura Oncology, Inc.
– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRASG12D inhibitors – SAN DIEGO, Oct. 04, 2023 ...
Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer
28 sept. 2023 07h30 HE
|
Kura Oncology, Inc.
– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors – – Company to include KRASG12C-mutant NSCLC in combination portion of Phase 1...
Kura Oncology to Participate in Cantor Global Healthcare Conference 2023
19 sept. 2023 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Appoints Brian Powl as Chief Commercial Officer
14 août 2023 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Second Quarter 2023 Financial Results
03 août 2023 16h05 HE
|
Kura Oncology, Inc.
– Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections – – First patients dosed in combination study of ziftomenib in NPM1-mutant and...
Kura Oncology to Report Second Quarter 2023 Financial Results
27 juil. 2023 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...